The findings indicated that fly species with resistance to one virus were generally also resistant to related viruses. Surprisingly, the study also found significant positive correlations in susceptibility, meaning species that struggled with one virus were also more susceptible to others, even those from entirely different viral families.

Dr. Ryan Imrie, now working at the MRC-University of Glasgow Centre for Virus Research, explained the significance of the study: “Large-scale tests like this help us understand how pathogens shift to new host species. This understanding could be applied to other animals, including humans.” The research is aimed at uncovering patterns in how viruses evolve and jump between hosts, an important step in predicting and preventing future pandemics.

Professor Ben Longdon, a lead researcher at Exeter’s Centre for Ecology and Conservation, further highlighted how virus-relatedness can help infer the behavior of emerging viruses. He cautioned, however, that even small mutations could cause viruses to acquire vastly different characteristics, complicating predictions.

The research measured susceptibility through the “viral load” method, which tracks how much a virus replicates within an infected species over a set period. The results suggested that some fly species may have evolved in environments with fewer viruses or may possess immune systems that viruses can easily exploit, making them more susceptible.

Notably, the study found no “trade-offs” in immunity, meaning species that were resistant to one virus did not show lower resistance to others, challenging previous assumptions about the cost of immunity in host species.

This research offers valuable insights into the evolutionary dynamics of viruses and hosts, providing a better understanding of viral behavior and immune system evolution.

The post Fruit Fly Species Found Vulnerable to Multiple Viruses appeared first on FolksTimes.

By using advanced artificial intelligence (AI) technology, the study analyzed over 50,000 eyes, creating detailed retinal maps with unprecedented precision. These maps offer new perspectives on how variations in retinal thickness correlate with a range of diseases, including neurodegenerative and metabolic disorders.

The retina, part of the central nervous system alongside the brain and spinal cord, is crucial to understanding conditions such as dementia and diabetes. This innovative study highlights how changes in the retina’s thickness could serve as a diagnostic tool for early detection of these diseases.

Dr. Vicki Jackson, lead researcher at WEHI, emphasized the groundbreaking potential of retinal imaging: “Our research shows that retinal imaging can act as a window into the brain, helping us detect neurological disorders like multiple sclerosis and other conditions early.”

The study also discovered new genetic factors that influence retinal thickness, providing deeper insight into the retina’s growth and its role in disease development. By analyzing over 50,000 retinal maps, researchers identified retinal thinning related to 294 genes, which may be pivotal in the onset and progression of diseases.

This discovery paves the way for using retinal imaging as a routine screening tool for various diseases, offering a non-invasive and accessible method for early diagnosis and disease management. The fine-scale measurements created in this study open new doors for precision medicine, potentially revolutionizing how we detect and track numerous diseases through simple eye examinations.

The post New Research Uncovers Retinal Thickness as Early Disease Marker appeared first on FolksTimes.

Shukla, who is also one of the prime astronauts for the Indian Space Research Organisation’s (ISRO) ambitious Gaganyaan mission, will serve as the pilot for the Ax-4 mission. This mission, managed by Axiom Space, will be commanded by Peggy Whitson, a former NASA astronaut and the Director of Human Spaceflight at Axiom Space. Alongside Shukla, the mission will feature two mission specialists—Slawosz Uznanski-Wisniewski from Poland and Tibor Kapu from Hungary.

The Ax-4 mission holds special significance as it will mark the return of human spaceflight for India, Poland, and Hungary. For these nations, this will be the first government-sponsored space mission in over 40 years, underscoring the growing international collaboration in space exploration.

A Distinguished Career and Space Training

Wing Commander Shubhanshu Shukla is no stranger to excellence. Commissioned into the IAF fighter wing in 2006, Shukla quickly rose through the ranks as a combat leader and test pilot. With over 2,000 hours of flight experience across a wide array of aircraft—including the Su-30 MKI, MiG-21, MiG-29, Jaguar, Hawk, Dornier, and An-32—Shukla has proven himself as a versatile and skilled pilot. His career culminated in his promotion to Group Captain in March 2024, reflecting his exceptional contributions to the IAF.

Shukla’s journey into space began in 2019 when he received an invitation from ISRO to train at the prestigious Yuri Gagarin Cosmonaut Training Center in Star City, Moscow. After a year of rigorous preparation, Shukla was selected as one of the elite astronauts for India’s Gaganyaan mission, set to launch in 2025. His role as the ‘Prime’ astronaut for the Gaganyaan mission was officially announced by Indian Prime Minister Narendra Modi on February 27, 2024.

India’s Growing Space Presence

Shubhanshu Shukla’s selection as the pilot for Ax-4 further strengthens India’s position in the global space community. The Ax-4 mission will be India’s second human spaceflight mission since 1984, the year when India first sent an astronaut, Rakesh Sharma, into space.

India’s space achievements have been growing at an unprecedented pace. From the historic success of the Chandrayaan-3 lunar landing to the successful launch of the Aditya L1 Solar Mission, ISRO has demonstrated its technological prowess on the global stage. The Gaganyaan program, which will launch three Indian astronauts to space for a 3-day mission, remains a top priority for the Indian government. The mission will test India’s human spaceflight capabilities by sending a crew to an orbit of 400 kilometers and returning them safely to Earth.

In addition to Gaganyaan, ISRO has continued to make strides in its technological innovations, including successful tests for reusable launch vehicles, expanding its satellite portfolio, and preparing for an Indian space station by 2035. On January 29, 2025, ISRO achieved a significant milestone with the launch of GSLV-F15 carrying the NVS-02 satellite, marking the 100th launch from the Sriharikota spaceport.

The Road Ahead

The selection of Wing Commander Shubhanshu Shukla for the Axiom Mission 4 is a testament to India’s growing contributions to space exploration. As Shukla prepares for his mission, he represents not only the Indian Air Force but also the aspirations of an entire nation as it strives to become a major player in space science and technology.

With missions like Gaganyaan, the establishment of a national space station, and continued international collaborations, India’s space sector is poised to continue its upward trajectory, achieving new milestones in the quest for knowledge and exploration beyond Earth.

The post Wing Commander Shubhanshu Shukla to Pilot Axiom Mission 4, Marking India’s Historic Return to Human Spaceflight appeared first on FolksTimes.

Post-acute sequelae of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection continue to affect millions worldwide. Cognitive impairment and fatigue are among the most common lingering symptoms, with cognitive impairment impacting 70% of patients. The ongoing effects of COVID-19 are particularly pronounced in older adults, especially women, who face heightened vulnerability due to factors such as menopause and the resulting increase in cognitive challenges.

Dr. Monica Christmas, associate medical director for The Menopause Society, commented on the findings, noting, “As the authors highlight, post-acute sequelae of severe acute respiratory coronavirus 2 infection significantly affects quality of life, often leading to severe disability. This effect is particularly pronounced in women, who already experience higher rates of cognitive impairment after menopause.” By identifying early risk factors like white blood cell count, healthcare providers could better address the long-term challenges COVID-19 poses, especially for these at-risk groups.

The study, based on secondary analysis from the Women’s Health Initiative, sought to understand whether preexisting risk factors could predict more severe outcomes for older, postmenopausal women. Researchers found that leukocyte count, a common clinical marker of systemic inflammation, was significantly associated with the severity of COVID-19 symptoms.

This breakthrough supports the hypothesis that low-grade inflammation, signaled by white blood cell levels, might not only be an outcome of severe COVID-19 infection but could also serve as an early indicator of who might face more significant illness. The study’s results provide promising evidence that monitoring leukocyte count could offer a cost-effective and easily accessible way to identify those at risk.

While the study’s results are compelling, the researchers emphasize the need for further investigation into the relationship between leukocyte count and COVID-19 outcomes. Nevertheless, this study offers hope for better management and treatment of COVID-19, particularly for the vulnerable populations most impacted by the disease’s lingering effects.

As researchers continue to explore the long-term consequences of COVID-19, understanding the role of systemic inflammation could play a crucial part in mitigating the pandemic’s ongoing health effects.

The post White Blood Cell Count: A Key Predictor of COVID-19 Severity, Study Finds appeared first on FolksTimes.

The study, published on January 22, 2025, reveals that individuals with greater amounts of fat embedded in their muscles are more likely to experience coronary microvascular dysfunction (CMD)—a condition where the tiny blood vessels in the heart become damaged. This dysfunction is closely linked to a higher risk of hospitalization or death due to heart attacks or heart failure.

While obesity is widely recognized as a major global health threat, the current reliance on BMI to assess cardiovascular risk may not be sufficient for all individuals, especially women. BMI has been shown to fail in accurately assessing the heart disease risks for those with higher muscle fat. In fact, for some people, particularly women, high BMI can reflect “benign” fat types that do not contribute to cardiovascular problems, Taqueti explained.

The research analyzed the muscle fat of 669 individuals, all of whom were undergoing evaluation for chest pain or shortness of breath at Brigham and Women’s Hospital. None of the participants had obstructive coronary artery disease. The study followed these patients for about six years, monitoring their heart health and hospitalizations for heart failure or heart attack. Those with higher amounts of intermuscular fat were more likely to develop CMD and subsequently experience severe heart-related events.

This groundbreaking study highlights the need for more precise measures of heart disease risk that go beyond traditional markers like BMI and waist circumference. It suggests that body composition, particularly fat within the muscles, plays a critical role in cardiovascular health, potentially offering new avenues for early detection and intervention.

Professor Taqueti’s team hopes these findings will lead to more personalized strategies for assessing and treating cardiovascular risks, especially for those whose BMI may not fully capture the dangers lurking beneath the surface.

The post Hidden Fat in Muscles Linked to Higher Heart Disease Risk, Study Reveals appeared first on FolksTimes.

Traditionally, understanding the electrical activity within heart cells, known as intracellular signals, has been a complex and invasive process. To capture these signals, scientists would need to penetrate the cells using microelectrodes, a technique that can damage the cells and complicate large-scale studies. However, this new method allows researchers to monitor these crucial signals without physically entering the cells, thereby avoiding damage and improving the feasibility of high-throughput testing.

The breakthrough hinges on a deep understanding of the relationship between the electrical signals that occur within the cells (intracellular signals) and those that can be measured from the cell’s surface (extracellular signals). As Zeinab Jahed, a senior author of the study and professor at UC San Diego, explains, “We discovered that extracellular signals hold the information we need to unlock the intracellular features that we’re interested in.”

While extracellular signals can be detected with less invasive methods, they typically provide limited details about the inner workings of the cells. Jahed likens it to “listening to a conversation through a wall—you can detect that communication is happening, but you miss the specific details.” In contrast, intracellular signals offer rich details but are typically captured through invasive, more technically demanding methods. By using AI, the team was able to correlate these two sets of signals and reconstruct the intracellular activity with remarkable accuracy.

A Step-By-Step Look at the Research

To develop this cutting-edge method, the researchers engineered an array of nanoscale, needle-shaped electrodes made from silica coated with platinum. These electrodes, each about 200 times smaller than a single heart muscle cell, were used to capture electrical signals from heart cells grown from stem cells. The heart muscle cells were placed on the electrode array, and a vast dataset was generated by recording thousands of pairs of extracellular and intracellular signals. The dataset also included responses of the cells to various drugs, providing valuable insights into cellular behavior under different conditions.

By analyzing these signal pairs, the team identified patterns and relationships between the extracellular and intracellular signals. This dataset became the foundation for training a deep learning AI model capable of predicting intracellular signals based solely on the extracellular data. The model demonstrated high precision in reconstructing the internal electrical activity of the heart cells, even in complex drug exposure scenarios.

Transforming Drug Testing and Personalized Medicine

One of the most significant implications of this new AI-driven technique is its potential to accelerate drug development, particularly in the field of cardiotoxicity testing. Every new pharmaceutical must undergo rigorous safety testing to ensure it does not negatively impact the heart. Part of this testing involves evaluating intracellular electrical signals from heart muscle cells, as even subtle changes in these signals can indicate potential harmful effects.

Currently, cardiotoxicity testing is a costly and time-consuming process, often requiring animal models, which don’t always predict human responses accurately. With this new method, researchers can conduct drug screening directly on human heart cells, providing a more accurate and relevant picture of how a drug might affect the heart. This not only has the potential to reduce the need for animal testing but also to streamline the drug development process, cutting both time and costs.

“This could dramatically reduce the time and cost of drug development,” said Jahed. “And because the cells used in these tests are derived from human stem cells, it also opens the door to personalized medicine. Drugs could be screened on patient-specific cells to predict how an individual might respond to these treatments.”

Expanding Beyond Cardiac Research

Although the current study focuses on heart muscle cells, the team is already working to expand this AI-driven method to other types of cells, such as neurons. The ability to noninvasively monitor and analyze cellular activity in various tissues could provide unprecedented insights into a wide array of cellular processes, potentially leading to breakthroughs in understanding and treating a variety of diseases.

By applying this technology to different cell types, researchers hope to gain a deeper understanding of cellular behaviors in both healthy and diseased states, paving the way for more personalized and effective treatments across a wide spectrum of medical conditions.

Conclusion

This innovative AI-driven technique marks a significant leap forward in noninvasive cellular monitoring, particularly in the study of heart cells. With the potential to improve drug testing, reduce the need for animal models, and enable personalized medicine, this breakthrough is poised to transform the future of cardiac research and drug development. As the technology continues to evolve, the possibilities for its application across a variety of cell types and medical fields are vast, offering new hope for patients and researchers alike.

The post AI-Driven Technique Revolutionizes Monitoring of Heart Cell Activity: A Breakthrough in Noninvasive Cardiac Research appeared first on FolksTimes.

The Indian National Space Promotion and Authorization Centre (IN-SPACe), an autonomous nodal agency under the Department of Space, played a pivotal role in facilitating this mission. On December 31, IN-SPACe announced the successful establishment and operationalization of 10 hosted payloads from Non-Government Entities (NGEs) aboard the POEM-4 module. These payloads represent a significant step forward in fostering collaboration between government space initiatives and private sector players.

In total, 24 PS4-Orbital Experiment Module (POEM-4) payloads were deployed onboard the PSLV-C60 SpaDeX mission, supporting a wide array of scientific and technological objectives. The inclusion of 10 payloads from NGEs underscores the growing participation of private entities in India’s space sector. Among these are notable contributions such as the RV-SAT1 from RV Engineering College, Bengaluru. This payload aims to study the behavior of gut bacteria Bacteroides thetaiotaomicron and prebiotic effects in microgravity. Another significant payload is the APEMS from Amity University Maharashtra, Mumbai, designed to examine growth-related changes in plant callus of Spinacia oleracea (spinach) under microgravity and natural gravity conditions.

Dr. Pawan Goenka, Chairman of IN-SPACe, emphasized the importance of missions like PSLV-C60/SPADEX in building capacity and reducing entry barriers for private players in the space sector. He noted, “The PSLV Orbital Experiment Module (POEM) is a practical solution deployed by ISRO that allows Indian start-ups, academic institutions, and research organizations to test their space technologies without the need to launch entire satellites. By making this platform accessible, we are reducing entry barriers and enabling a wider range of entities to contribute to the space sector. At IN-SPACe, our role is to create opportunities for such collaborations and ensure that India’s private sector can grow alongside advancements in space technology.”

The POEM platform, equipped with essential capabilities such as power supply, telemetry, and command support, enables seamless operations for onboard experiments. By leveraging existing infrastructure, it provides an economical approach to diverse research pursuits. This innovative model not only enhances the scope for scientific exploration but also helps NGEs in getting their payloads space-qualified, thereby bolstering their future satellite launch missions.

As India continues to advance its space program, missions like PSLV-C60/SPADEX exemplify the country’s commitment to fostering innovation and collaboration. With platforms like POEM, India’s space ecosystem is poised to achieve new heights, enabling a broader spectrum of contributors to participate in and benefit from space exploration.

The post “PSLV-C60: Empowering Space Innovation with POEM-4 and Private Collaboration.” appeared first on FolksTimes.

The research, led by the International Head and Neck Cancer Epidemiology Consortium, pooled data from 14 studies involving over 9,500 patients with head and neck cancer and more than 15,700 cancer-free controls. The study results indicate that individuals who consume coffee and tea regularly may lower their risk of developing head and neck cancers.

The analysis revealed that those who drank more than four cups of caffeinated coffee daily had a 17% lower likelihood of developing head and neck cancer compared to non-coffee drinkers. Additionally, regular coffee consumption was associated with a 30% reduced risk of oral cavity cancer and a 22% lower risk of throat cancer.

Among the most notable findings was the significant protective effect of caffeinated coffee against hypopharyngeal cancer—a type of cancer located at the bottom of the throat. Drinking 3-4 cups of caffeinated coffee daily was linked to a 41% reduction in the risk of hypopharyngeal cancer. Even decaffeinated coffee showed a protective benefit, with decaf drinkers experiencing a 25% lower risk of oral cavity cancer.

Tea consumption also appeared to offer protective effects, with a 29% reduced risk of hypopharyngeal cancer. The study found that drinking one cup or fewer of tea daily was associated with a 9% reduction in the overall risk of head and neck cancer and a 27% lower risk of hypopharyngeal cancer. However, the study also highlighted that drinking more than one cup of tea daily was linked to a 38% increased risk of developing laryngeal cancer.

These results suggest a complex relationship between coffee, tea, and various types of head and neck cancer. While caffeine and tea are often associated with health benefits, the study shows that their impact may vary depending on the specific type of cancer. Decaffeinated coffee, for example, was found to have a beneficial effect, indicating that factors beyond caffeine may play a role in reducing cancer risk.

Despite the promising findings, the researchers stressed the need for further studies to better understand how coffee and tea consumption affect cancer risk. Senior author Dr. Yuan-Chin Amy Lee from the Huntsman Cancer Institute and the University of Utah School of Medicine emphasized the importance of additional research in this area.

“Coffee and tea habits are fairly complex, and these findings support the need for more data and further studies around the impact that coffee and tea can have on reducing cancer risk,” Dr. Lee said.

While the study provides compelling evidence that coffee and tea may help reduce the risk of head and neck cancers, more research is needed to fully understand the extent of their protective effects. The findings advocate for the inclusion of these beverages in a balanced diet, but they also call for continued scientific inquiry into their potential role in cancer prevention.

The post “Drinking Coffee and Tea May Reduce the Risk of Head and Neck Cancer” appeared first on FolksTimes.

The study, led by Dr. Jeffrey L. Carson, provost and Distinguished Professor of medicine at Rutgers Robert Wood Johnson Medical School, confirms the results of earlier research. The 2023 MINT (Myocardial Infarction and Transfusion) trial focused on how blood transfusions affected anemic patients following a heart attack. The study highlighted that those who received less blood showed poorer outcomes compared to those who received more.

Following the trial, Dr. Carson and his team sought to deepen their understanding of blood transfusion strategies by combining data from similar trials to provide more accurate treatment estimates. The team collaborated with researchers in France and the U.S. and analyzed data from four clinical trials involving a total of 4,311 heart attack patients who also had low blood counts.

Half of the patients received fewer blood transfusions, while the other half received a higher volume. The trials then compared the frequency of death or recurrent heart attacks at 30 days and six months post-treatment.

Published in NEJM Evidence, the findings from this analysis suggest that while giving less blood did not definitively increase the risk of death or heart attacks at 30 days, it was associated with a higher mortality risk at six months. The original clinical trials included patients who had previously suffered from heart attacks, heart failure, diabetes, or kidney disease, with an average participant age of 72, and nearly half of them were women.

The study showed a modest 2.4% reduction in mortality or recurrent heart attacks when a more liberal blood transfusion approach was used. Although this result was not statistically significant at the 30-day mark, Dr. Carson emphasized that the data strongly indicate that more transfusions can improve patient outcomes over a longer period.

Dr. Carson commented, “The results of this analysis show that giving more blood to anemic patients with heart attacks can save lives at six months.”

Both studies were funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. Dr. Carson, who has spent nearly two decades researching the effects of red blood cell transfusion strategies, played a pivotal role in the development of transfusion guidelines established in 2012. These guidelines, which were updated last year in the Journal of the American Medical Association, emphasize a more individualized approach to treatment, taking into account patients’ underlying health conditions, preferences, and symptoms.

This new study adds weight to the growing body of research suggesting that tailored transfusion strategies could be critical in improving outcomes for heart attack patients with anemia.

The post Study Suggests Increased Blood Transfusions Can Save Lives in Anemic Heart Attack Patients appeared first on FolksTimes.

To address challenges in understanding this process, a research team led by Associate Professor Hiroshi Kadokura and Professor Hideki Taguchi from the Institute of Science in Tokyo has developed an innovative ‘reporter’ molecule that can detect ER-related problems during protein synthesis. This breakthrough aims to shed light on the disruptions in protein translocation to the ER or disulfide bond formation, which can lead to several diseases.

Currently, studying these mechanisms is hindered by limited tools or the need for expensive equipment and meticulous measurements. The researchers overcame these challenges by designing a reporter molecule based on firefly luciferase (FLuc), a bioluminescent enzyme that produces light when it catalyzes the oxidation of D-luciferin in the presence of oxygen, ATP, and magnesium ions (Mg2+).

The researchers adapted the FLuc enzyme to be inactive when disulfide bonds form in the ER, but active if disulfide bonds do not form or if the enzyme remains in the cytosol. By introducing specific modifications to target the compound to the ER, and making it more prone to misfolding, they developed a system that could easily detect problems in protein translocation and disulfide bond formation.

The FLuc-based reporter system can also detect which of the two issues (translocation or bond formation) is responsible for any observed activation. The researchers demonstrated its effectiveness by running experiments where the redox environment of the ER was chemically altered, disrupting disulfide bond formation. The reporter was also able to detect defects in protein translocation induced by a potential anti-HIV drug, signaling the successful inhibition of the virus.

“Given that luciferase-based assays are well-suited for high-throughput platforms, we suggest that this approach will facilitate large-scale screening of small molecules that specifically block the biosynthesis of harmful secretory pathway proteins,” said Kadokura.

The team’s reporter system offers several advantages over existing methods, including simplicity, robustness against environmental fluctuations, and high reproducibility. Taguchi added, “Our reporter system will serve as a valuable tool across various fields related to secretory pathway proteins, extending beyond fundamental studies.”

This breakthrough in understanding protein synthesis and its related diseases could pave the way for new medical advances and treatments, offering hope for better diagnosis and intervention in the future.

The post Japanese Researchers Develop Innovative Reporter Molecule to Detect Protein Synthesis Issues in Cells appeared first on FolksTimes.